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http://dx.doi.org/10.1016/j.jmii.2013The widespread multidrug-resistant Enterobacteriaceae pose a serious therapeutic challenge.
Colistin and tigecycline are potential antimicrobial agents for treating infections caused by
extended-spectrum b-lactamase (ESBL)-producing Enterobacteriaceae. We evaluated the in-vi-
tro activity of colistin sulfate against 253 ESBL producers isolated from patients admitted to a
medical center in southern Taiwan (Escherichia coli, nZ 82; Klebsiella pneumoniae, nZ 102;
Enterobacter cloacae, nZ 34; and Serratia marcescens, nZ 35). Colistin showed promising
in-vitro activity against E. coli, K. pneumoniae, and E. cloacae, but not S. marcescens. One
ESBL-producing K. pneumoniae strain with resistance to carbapenems (ertapenem, imipenem,
and meropenem) was selected for time-killing studies. A combination of colistin and tigecycline
showed synergism, but there was an inoculum effect. In conclusion, colistin was active against
most ESBL-producingEnterobacteriaceae, anda combination of colistinwith tigecyclinewas syn-
ergistic against some highly resistant strains, even those with carbapenem resistance.
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Multidrug-resistant Enterobacteriaceae are ubiquitous and
pose a serious therapeutic challenge. The production of
plasmid-mediated extended-spectrum b-lactamases
(ESBLs) by Enterobacteriaceae subsequent to extensive use
of broad-spectrum antibiotics, has limited the use of anti-
biotics to carbapenems, which are used for serious in-
fections.1 However, increased use of carbapenems leads to
the selection of carbapenem-resistant Enterobacteriaceae.
Colistin and tigecyclin have been suggested as alternatives
to carbapenems for the treatment of infections caused by
ESBL-producing Enterobacteriaceae in order to avoid
selecting for carbapenem resistance.
Colistin, discovered in 1949, was gradually phased out
from clinical use in the early 1980s because of its high
incidence of nephrotoxicity.2 Two forms of colistin are
commercially available: Colistin sulfate for oral and topical
use, and colistimethate sodium (also called sodium colistin
methanesulfonate) for parenteral use.2 Colistin sulfate is
stable, while colistimethate sodium is readily hydrolyzed to
methanesulfonated derivatives. Colistin sulfate is therefore
used in antimicrobial susceptibility tests.3,4 There are very
few studies investigating colistin use for the treatment of
infections caused by ESBL-producing Enterobacteriaceae in
Taiwan. One study reported that the 22 isolates of
Escherichia coli and 16 isolates of Klebsiella pneumoniae in
northern Taiwan that produce ESBLs were most susceptible
to colistin (91% and 100%, respectively).5 However, another
study from central Taiwan reported that colistin showed
poor in-vitro activity against three members of the Enter-
obacteriaceae family (Enterobacter cloacae, Citrobacter
freundii, and Serratia marcescens).6 In this study, we
evaluated the in-vitro activity of colistin sulfate against
ESBL-producing E. coli, K. pneumoniae, E. cloacae, and S.
marcescens isolates from southern Taiwan. We also used
time-killing studies to evaluate the synergism of colistin
and tigecycline activity against one strain of ESBL-
producing K. pneumoniae (designed Kp340) with resis-
tance to carbapenems.Materials and methods
Isolates
The ESBL-producing isolates of Enterobacteriaceae were
collected from the Chi Mei Medical Center, Taiwan, in 2009
and were identified on the basis of routine microbiologic
methods (Phoenix system, Becton Dickinson Company,Table 1 The colistin MIC distribution (n, %) for ESBL-producing
Organisms (n Z 253) MIC  1 mg/mL MI
Escherichia coli (82) 74 (90%) 8
Klebsiella pneumoniae (102) 41 (40%) 60
Enterobacter cloacae (34) 9 (26%) 24
Serratia marcescens (35) 0 0
ESBL Z extended-spectrum b-lactamase; MIC Z minimal inhibitory cBaltimore, MD, USA). All isolates were subcultured and
frozen at 70C. ESBL producers were tested using the
phenotypic confirmatory disc diffusion method described
by the Clinical Laboratory Standard Institute (CLSI).4
Antimicrobial susceptibility testing
Minimal inhibitory concentrations (MICs) for colistin sulfate
(Sigma Chemical Company, St. Louis, MO, USA) and tige-
cycline (Wyeth, Puerto Rico, USA) were determined by the
standard agar dilution method described by CLSI.3 There is
no CLSI recommendation for colistin susceptible break-
points against Enterobacteriaceae, while the CSLI recom-
mendations for Pseudomonas aeruginosa and Acinetobacter
baumannii are as follows: (susceptible, 2 mg/mL; inter-
mediately resistant, 4 mg/mL; resistant, 8 mg/mL and
susceptible, 2 mg/mL; resistant, 4 mg/mL, respec-
tively).4 According to the British Society for Antimicrobial
Chemotherapy Working Party on Susceptibility Testing, the
susceptible MIC breakpoint for colistin against Enter-
obacteriaceae is 4 mg/mL, and the strain should be
considered resistant if the MIC > 4 mg/mL.7 We applied the
British Society MIC breakpoints to our results.
Time-killing study
One ESBL-producing K. pneumoniae urine isolate (Kp340)
that was resistant to ertapenem, imipenem, and mer-
openem was recovered from a host who was previously
exposed to tigecycline and meropenem. We used the Kp340
isolate to evaluate the synergistic activity of colistin (MIC,
1 mg/mL) and tigecycline (MIC, 4 mg/mL) using 1/2  MIC for
each drug concentration alone or for the combination of
both drugs. We also performed time-kill studies using 1/
4  MIC for the combination of both drugs. Serial samples
(baseline, 2, 4, 6, 8, 12, 24 h) were obtained over a time
period of 24 hours. We used two different final inocula of
colony-forming units (CFU)/mL with a 100-fold difference
in densities. The standard inoculum was 5  105 CFU/mL,
and the high inoculum was 5  107 CFU/mL. Bactericidal
activity was defined as a 3-log10 CFU/mL decrease in
viable cell counts compared to the original inoculum. The
lower limit of detection was 100 CFU/mL.
Results and discussion
A total of 253 ESBL-producing Enterobacteriaceae were
collected, which included 82 strains of E. coli (blood, nZ 7;
sputum, nZ 15; urine, nZ 37; wound pus, nZ 15, ascites,Enterobacteriaceae
C Z 2 mg/mL MIC Z 4 mg/mL MIC 8 mg/mL
(10%) 0 0
(59%) 1 (1%) 0
(71) 1 (3%) 0
0 35 (100%)
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Figure 1. Survival curves of Kp340 standard inoculum (A) and high inoculum (B) using 1/2  MIC and 1/4 MIC drug concentrations
of colistin and tigecycline. CS Z colistin; ESBL Z extended-spectrum b-lactamase; MIC Z minimal inhibitory concentration;
TGC Z tigecycline.
Colistin is active against ESBL producers 701nZ 8), 102 strains of K. pneumoniae (blood, nZ 15; sputum,
nZ 40; urine, nZ 30; wound pus, nZ 17), 34 strains of E.
cloacae (blood, n Z 4; urine, n Z 19; wound pus, n Z 8;
ascites, n Z 3), and 35 strains of S. marcescens (blood,
nZ 12; sputum, nZ 5; urine, nZ 18).
The activity of colistin against the 253 bacterial strains is
shown in Table 1. None of the ESBL-producing E. coli, K.
pneumoniae, and E. cloacae strains had an MIC > 4 mg/mL,
while the ESBL-producing S. marcescens strains did. All ESBL-
producing E. coli strains (nZ 82) hadMICs 2 mg/mL,with an
MIC90 value of 1 mg/mL. All the ESBL-producing K. pneumo-
niae (n Z 102) and E. cloacae (n Z 34) strains had MIC
values 4 mg/ml, and the MIC90 values were 2 mg/ml. Colistin
showed significant activity against ESBL-producing strains of
E. coli, K. pneumoniae and E. cloacae but was less active
against ESBL-producing S. marcescens, which had an MIC100
value > 4 mg/mL. The 100% resistance was predictable since
S. marcescens is inherently resistant to colistin.8 Although
there are encouraging data describing colistin activity against
Pseudomonas and Acinetobacter isolates,2 the activity of
colistin against multidrug-resistant Enterobacteriaceae re-
mains unclear.8,9 There has also been a rapid and steep in-
crease in colistin resistance in K. pneumoniae strains.10
We showed that a combination of colistin and tigecy-
cline, at 1/2  MIC as well as the 1/4  MIC drug concen-
trations had synergistic activity against the standard
inoculum beginning at 2 hours after inoculation and lasting
24 hours (Fig. 1A). However, although both drug concen-
trations were less active against the high inoculum, only
1/2  MIC drug concentration of both drugs exhibited the
synergistic, bactericidal effects (Fig. 1B). The standard
inoculum of bacterial density treated with colistin alone at
1/2  MIC drug concentration showed a rapid regrowth of
bacteria (Fig. 1A). In contrast, tigecycline alone at 1/2  MIC drug concentration did not exert a bacteriostatic
effect on the high inoculum of bacterial density (Fig. 1B).
Our data suggest that a combination of colistin and tige-
cycline could be an alternative to carbapenem to treat
infections caused by the ESBL producers, especially those
which are resistant to carbapenem.
In conclusion, colistin has promising in-vitro activity
against ESBL-producing Enterobacteriaceae, including E.
coli, K. pneumoniae and E. cloacae. To avoid rapid induc-
tion of colistin resistance, a combination of colistin and
tigecycline may be considered as an alternative therapeutic
option to treat multidrug-resistant Enterobacteriaceae in-
fections. However, it is important to keep in mind the
inoculum effect.
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